Tempus AI to Showcase AI-Driven Medicine Strategy at Key Conference

CHICAGO, IL – January 06, 2026 – All eyes in the healthcare and technology sectors will turn to San Francisco next week as Tempus AI (NASDAQ: TEM) takes the stage at the 44th Annual J.P. Morgan Healthcare Conference. Founder and CEO Eric Lefkofsky is scheduled to deliver a highly anticipated presentation on January 12th, offering a crucial update on the company's mission to reshape precision medicine through artificial intelligence. For the technology firm, which went public in a high-profile IPO in June 2024, this presentation is more than a routine update; it's a strategic spotlight on its progress, vision, and path to profitability in a rapidly evolving market.

The J.P. Morgan conference is widely regarded as the premier event for the healthcare industry, a place where multi-billion dollar deals are born and the trajectories of companies are set for the year ahead. A presentation here provides a powerful platform to engage with investors, analysts, and potential strategic partners. For Tempus, the stakes are high as it seeks to solidify its position as a leader in the convergence of AI, big data, and medicine.

A Personal Mission Fueling a Data-Driven Revolution

At the heart of Tempus AI is a deeply personal story that has become the company's driving force. Eric Lefkofsky, a serial entrepreneur known for co-founding companies like Groupon, launched Tempus in 2015 after his wife was diagnosed with breast cancer. He was struck by the fragmented and underutilized nature of patient data within the healthcare system, identifying what he called a fundamental "data problem."

His vision was to create a company that could systematically structure and analyze the vast troves of clinical and molecular data to provide physicians with actionable insights. The central thesis was to build one of the world's largest libraries of multimodal data—combining genomics, pathology images, clinical histories, and more—and apply sophisticated AI and machine learning models to it. The ultimate goal is to ensure that each patient benefits from the collective experience of all who came before them, enabling a new era of personalized care.

This founder-led vision has guided Tempus from a private startup to a publicly traded entity, raising approximately $410.7 million in its IPO. Lefkofsky's narrative has consistently centered on creating "Intelligent Diagnostics"—tools that don't just return a lab result, but connect that result to a patient's unique clinical profile to guide treatment decisions in near real-time.

Building the 'Data Moat' in a Competitive Landscape

Tempus's strategy hinges on creating what industry observers call a "durable data moat." With over 400 petabytes of data and more than 45 million de-identified research records, the company's vast and growing dataset is its most valuable asset. This library powers an operating system designed to make data accessible for two primary purposes: helping physicians deliver personalized care and helping pharmaceutical partners accelerate the discovery and development of new therapeutics.

Recent moves have demonstrated a clear strategy to widen this moat. In August 2025, Tempus acquired Paige.AI, Inc. for $81.3 million, adding an estimated 7 million digitized pathology slides to its data library. This acquisition significantly enhances its capabilities in AI-powered pathology, a key battleground in the precision medicine space.

The company has also been aggressively expanding its product portfolio. Its FDA-approved solid tumor DNA test, xT CDx, has gained significant traction, and the company is expanding its liquid biopsy (xF) and minimal residual disease (xM) testing platforms. Furthermore, Tempus is embedding its technology directly into clinical workflows. Its generative AI assistant, Tempus One, is being integrated into electronic health record (EHR) systems to support oncologists, while its Tempus Next platform provides AI-driven care pathway intelligence for diseases like breast cancer.

This aggressive expansion is necessary in a fiercely competitive market. Tempus contends with a range of players, from specialized firms like PathAI and Flatiron Health (a unit of Roche) to tech giants like Google and NVIDIA, all vying for a piece of the burgeoning AI in healthcare market, which is projected to be worth hundreds of billions of dollars by the next decade. Tempus's key differentiator remains its focus on building a comprehensive, multimodal data ecosystem that is difficult for competitors to replicate.

Balancing Growth with a Clear Path to Profitability

Since its IPO, investors have been closely watching Tempus's financial performance. The company has delivered impressive top-line growth, reporting a nearly 90% year-over-year revenue jump to $314.6 million in the second quarter of 2025. It has laid out a goal of achieving sustainable 25% annual revenue growth over the next three years.

However, growth has come at a cost, and the company has historically been a money-losing enterprise. A key focus for Lefkofsky's upcoming presentation will be reinforcing the company's path to profitability. At the time of the IPO, he stated an expectation for Tempus to become cash flow positive and adjusted EBITDA positive sometime in 2025, a milestone the investment community is eagerly awaiting confirmation on. Wall Street analysts currently hold a consensus "Moderate Buy" rating on the stock, with average 12-month price targets suggesting significant upside from its current trading price. This indicates cautious optimism, contingent on the company executing its strategic and financial plans.

Investors will also be listening for any updates on a patent infringement lawsuit filed by competitor Guardant Health shortly after the IPO. While Tempus has stated its intent to "vigorously defend" itself, the overhang from litigation remains a factor in investor calculations. The J.P. Morgan stage offers a prime opportunity for Lefkofsky to project confidence and focus on the company's forward momentum.

As Lefkofsky prepares to address the healthcare world, the audience will be looking for concrete evidence that Tempus's grand vision is translating into durable commercial success. Key items on the checklist will include updates on the integration of Paige.AI, the adoption rates of its AI-enabled platforms like Tempus One, the signing of new partnerships with major pharmaceutical companies, and, most importantly, a clear and credible update on its journey toward sustained profitability.